Next Phase Newsletter

A US subsidiary of a mid-sized pharma company in Asia has a robust pipeline of antibody-based and small molecule therapeutics. The firm is currently seeking strategic partnerships involving next-gen technology platforms and novel targets and molecules in the fields of oncology, autoimmune, metabolic, cardiovascular, and other disease areas with unmet medical needs. As one of the leaders in the field of antibody-drug conjugates (ADCs), there is particular interest in partnering with early-stage biotechs that are developing first-in-class antibodies. 
 
The firm is primarily interested in licensing or co-developing antibody-based therapeutics, including those with novel targets, structures/designs, conjugation chemistries, and linker-payload strategies. 
 
The firm has no specific requirements for the company and management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment firm backed by a prominent family office currently manages a fund that is focused exclusively on life sciences & healthcare. The firm is focused on investing early-stage companies and open to global opportunities. 
 
The firm seeks to invest in therapeutics, diagnostics, and digital health companies and has no particular preference on specific types of technologies or disease area/indication. The firm prefers to see strong pre-clinical data, and is open to both pre-clinical and clinical projects. The firm does not invest in medical device companies at this time. In addition, the firm invests in other venture capital firms.  
 
The firm seeks to support companies with innovative technology, and is open to working with both first-time and experienced management teams. The firm can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A seed fund based in the US focuses on applied AI technologies and invests in three verticals: Digital Health, Enterprise, and Automation. The firm invests $ 500K – $1.5M in seed-stage companies based in the US with capital reserved for follow-ons. 
 
Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will co Calibri (Body) nsider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery. 
 
The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture studio and investment firm based in Asia currently manages a portfolio with half of the companies from their country of origin, and the half from across the globe (mostly USA, but some in Europe and Asia). The firm invests primarily in Seed to Pre-Series A rounds and focuses on life science and healthcare investments, with typical check sizes around $1-2M. The firm actively seeks global opportunities. 
 
The firm is agnostic towards sectors and indication areas. The firm has invested across all life science sectors, with a diverse portfolio in therapeutics, medical devices, diagnostics, and digital health. As an early-stage focused investor, the firm welcomes projects that are as early as idea or conception stage, and is open to pre-clinical stage companies.  

Previously, the firm had a focus on oncology, infectious disease, cardiovascular disease, and CNS. Regarding diagnostics, the firm had an additional focus on -omics and AI-based diagnostics, as well as infectious disease point-of-care diagnostics. For digital health, the firm is interested in precision medicine drug discovery, wearable sensors, digital therapeutics, home healthcare, and hospital tools. 
 
Though the firm does not have specific areas of interest and has broad interests in life sciences, the firm prioritizes areas with truly unmet need where there has not been enough advancements in delivering a therapeutic solution, and looks for novel technologies that have the potential to address a wide market. To date, the firm has not led investment rounds, but is open to co-leading in the future.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Founded in 2018, the corporate venture arm of a leading global Contract Research, Development and Manufacturing Organization is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The fund primarily seeks opportunities in the US, and is open to China and Europe as well. The fund does not lead rounds and prefers companies with a lead investor in place. Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The fund makes equity investments only and does not have an equity-for-service model. 
 
Separately from the corporate venture arm, the parent corporation also runs a program which collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biotech assets development. Startups must be an active participant or referred by a Program Partner to be eligible. 

The fund will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy. 

The fund does not lead investments rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first-time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm founded in 2014 is managing $150 million fund on behalf of a large, not-for-profit health system in the United States. The firm has closed a second $150 million venture and growth equity fund. 
 
As of 2025, the firm has initially closed a third fund and spun out as an independent venture capital firm. The firm has committed $150M, and the firm will seek to have a final close later in the year with additional LPs. Typical equity allocations had ranged from $8-15 million over the life of a company. The firm is looking primarily for opportunities across the US, and the firm would consider international companies with strong US advocacy and technology that can be deployed to the US market. 

The firm is looking for innovative medical technologies that are in line with the organization’s mission, improve quality and convenience, lower cost and improve health outcomes. Examples may include patient management systems for healthcare providers, home care systems, or monitoring devices for chronic disease management. The firm typically works with mature companies with revenue, consumer traction, or some validation on their technology. 

The firm is looking for solid management teams that show track records of success. The firm provides healthcare system expertise to portfolio companies to refine existing solutions, while expanding their adoption within and beyond its healthcare system. Providence Ventures is open to investing as a lead or co-investing along a syndicate. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Founded in 1973, a private equity firm headquartered in Tokyo, Japan has a total capital commitment of its investment funds in Japan and overseas have approximately $8.5B USD. The life science investment team invests in breakthrough innovations that potentially addresses unmet medical need. The firm has a dedicated life science investment team and invests in early and venture stage companies. For life science, the firm invests within $10M USD per round. The firm invests opportunistically in the life sciences. The firm seeks an opportunity to invest in innovative therapeutics, medical devices, digital health, diagnostics, and healthcare services that are in discovery/development stage. The firm prioritizes new IP/NCE and modality over repurposed or reformulated products. The firm generally requires a seat on the board of directors or observers. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.